OMEICOS is working closely together with the research group of John Seubert to investigate the effect of OMEICOS’ compounds in indications, associated with mitochondrial dysfunction.John’s research is focused on investigating the role of CYP epoxygenase metabolites in maintaining tissue homeostasis and reducing injury with a special focus on cardioprotection, ischemia-reperfusion, mitochondria, toxicology, the cytochrome P450 system and mechanisms of cellular death.
